Animal stem cell therapy market seen reaching $507.9M by 2035

Market Research Future projects the global animal stem cell therapy market will grow from $305.76 million in 2026 to $507.90 million by 2035, driven by rising chronic disease in companion animals, easier regulatory pathways and growing pet ownership. North America remains the biggest market, while Asia-Pacific is expected to expand fastest. Why it matters: - The market is projected to expand at a 5.80% CAGR from 2026 to 2035, pointing to steady demand for veterinary regenerative medicine. - Growth is tied to chronic conditions in pets, especially osteoarthritis, which drives most lameness and joint disease cases. - Easier approvals and broader pet spending are helping turn stem cell therapy from a niche service into a mainstream veterinary option. What happened: - Market Research Future said the global animal stem cell therapy market will rise from $305.76 million in 2026 to $507.90 million by 2035. - The report estimated the market at $289.00 million in 2025. - The forecast was released June 16, 2026. - The report highlights rising chronic musculoskeletal disease in companion animals, regulatory modernization and pet humanization as the main growth drivers. The details: - Osteoarthritis accounts for about 80% of lameness cases in dogs and cats, making it the biggest clinical driver in the market. - A 2024 study cited in the report found chronic kidney disease incidence of 2.64% across 2,456 dogs examined. - The USDA Center for Veterinary Biologics streamlined licensing for autologous stem cell products in 2023, cutting average approval timelines by an estimated 14 months. - The European Medicines Agency issued updated guidance on advanced therapy veterinary medicinal products, with more than EUR 12 million in compliance investment across the EU. - Japan’s Ministry of Agriculture, Forestry and Fisheries created a conditional approval category for veterinary cell therapies in 2024. - The report said about 3.1 million dogs and cats entered U.S. shelters in the first half of 2024. - A free sample is available here . - The full report is available here . Between the lines: - The forecast suggests demand is becoming structurally durable because pet care spending is less discretionary than many consumer health categories. - Regulatory clarity is lowering barriers for commercial launch and helping capital flow into veterinary cell therapy pipelines. - Pet ownership trends, especially among millennial and Gen-Z owners, are widening willingness to pay for advanced treatment. - The report also points to a shift from experimental use toward clinic-ready, reimbursable or higher-value specialty care. What’s next: - Autologous stem cell therapy is expected to remain the largest type segment, with about 58% revenue share in 2025. - Allogeneic stem cell therapy is forecast to be the fastest-growing type segment at 6.90% CAGR through 2035. - Veterinary hospitals are expected to remain the largest end-user group, while research institutes are projected to grow fastest. - North America is expected to remain dominant, but Asia-Pacific is projected to be the fastest-growing region at 7.2% CAGR. - The report expects precision veterinary medicine, biomarker-guided therapy and AI-driven diagnostics to become more common by 2030. - Early studies cited by the report found synovial fluid biomarker panels could predict osteoarthritis treatment response with 78% accuracy. The bottom line: - Animal stem cell therapy is moving from a specialized niche toward a broader veterinary treatment category, with growth anchored by chronic disease, easier regulation and rising pet spending.